fashion -WSS

fashion

author：explore 2025-10-02 12:32:26 - browse：2

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Reporting on presidential health from Reagan to Trump and Biden

Wikipedia

WSS

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Hospitals are piloting generative AI tools as regulators play catch

Congress may force more Covid

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Obamacare plans could cover weight loss drugs

hotspot

fashion

explore

As demand for Covid shots wanes, Moderna seeks its next success

Commercial surrogacy can be ethical, despite pope’s claims

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Measles policy set amid Florida outbreak alarms vaccine proponents

Wildfire smoke exposes gaps in outdoor worker protections

Obamacare plans could cover weight loss drugs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Secretariat’s lessons for human medicine

Drug repurposing or repositioning? The language matters

Even great ERs can’t make up for American health disparities

knowledge

Elevance, SCAN deals highlight health insurer acquisition scrutiny

A $475,000 price tag for a new cancer drug: crazy or meh?

General Catalyst, Summa Health deal will turn on physician buy

FDA drug safety: Singulair case shows systemic surveillance flaws

Woodcock on FDA’s accelerated approval and her next chapter

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Wikipedia

Wikipedia

focus

focus